Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should Patents On REMS Distribution Restrictions Be Banned?

This article was originally published in The Pink Sheet Daily

Executive Summary

Citing the use of Risk Evaluation and Mitigation Strategies to delay generic entry, Boston researchers urge Congress to revisit an “unintended consequence” created by the 2007 FDA Amendments Act.

Advertisement

Related Content

REMS Modification Guidance Coming As FDA Rejects Petition For Shared REMS Rules
Generic Companies Gain Little From FDA Decision On Access To REMS Drugs
Shared REMS Systems Show Challenges Of Standardization – Could PDUFA V Help?
Brand, Generic Disputes Over Access Move Beyond REMS Restrictions
REMS Hurdles To Generic Entry: From Brand Access To Patent Claims
PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel